News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Ventracor Limited Release: Preparing For EU Market Launch
June 19, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Ventracor Limited (ASX: VCR) today announced the first patient has been implanted with the VentrAssist in a new study designed to build on clinical momentum from the CE Mark Trial and prepare for European market launch.
Twitter
LinkedIn
Facebook
Email
Print
Australia
MORE ON THIS TOPIC
Insights
Stability, speed and strategy: Inside Australia’s early‑stage edge
October 29, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Insights
Australia’s clinical trial advantage gains ground amid U.S. uncertainty
October 26, 2026
·
4 min read
·
Jennifer C. Smith-Parker
China
Beyond China: Five other overseas destinations for biopharma dollars
September 9, 2026
·
8 min read
·
Tristan Manalac
Insights
New UK/EU Rules and AI Adoption Define CRO Priorities for 2026
December 3, 2025
·
4 min read
·
Jennifer C. Smith-Parker
